**Indivior Reports Financial Results, Strategic Shifts**

Indivior PLC, a pharmaceutical company specializing in opioid use disorder (OUD) treatments, reported its financial results, highlighting a 4% increase in net revenue, reaching $1.239 billion for the year ended December 31, 2025, compared to $1.188 billion in 2024. The company's operating income saw a significant rise, reaching $262 million, a 594% increase from the $38 million reported in the previous year. Net income also experienced a substantial turnaround, reporting $210 million compared to $7 million in 2024, with diluted earnings per share at $1.64, a notable shift from $0.05 in the prior year. The growth was primarily driven by SUBLOCADE, which accounted for 69% of the total net revenue, marking a 13% increase in sales to $856 million, while other buprenorphine-based sublingual products contributed 28% of the net revenue.

The company underwent several strategic developments during the year, including CEO and executive transitions, with Joseph Ciaffoni appointed as CEO in May 2025. Indivior also restructured its Research & Development and Medical Affairs organizations, leading to the closure of three related locations. In October 2025, the company announced it would cease operations and discontinue the sale of its products in several markets, including the U.K., Ireland, Sweden, Israel, Finland, and Italy, to optimize its Rest of World business. The company's shares were included in the U.S. Russell 2000 and 3000 indices on June 30, 2025, and the S&P SmallCap 600 index on December 22, 2025.

Key operational developments included the FDA approval of label changes for SUBLOCADE, including a rapid initiation protocol and alternative injection sites. The company's U.S. sales force ceased promoting SUBOXONE Film as part of the Resolution Agreement with the Department of Justice (DOJ). The company completed its obligations under the Corporate Integrity Agreement (CIA) in July 2025 and satisfied its remaining obligations under the Resolution Agreement in November 2025. As of December 31, 2025, the company employed 838 people worldwide, with 593 located in the U.S. and 245 outside the U.S.

Looking ahead, Indivior anticipates continued growth in U.S. SUBLOCADE net revenue in 2026, driven by LAI category growth and stable category share. However, competitive pressures are expected to continue to adversely impact SUBOXONE Film pricing and volume, resulting in an expected decline in SUBOXONE Film net revenue in 2026. Rest of World net revenue is expected to decline as a result of the exit from certain non-U.S. markets. The company expects negligible revenues from PERSERIS and OPVEE in 2026, as the company is no longer actively marketing these products. As a result of these factors, the company's total net revenue in 2026 is expected to decline compared to 2025. The company's shares were included in the U.S. Russell 2000 and 3000 indices on June 30, 2025, and the S&P SmallCap 600 index on December 22, 2025.

About Indivior Pharmaceuticals, Inc.

Indivior PLC is a global pharmaceutical company dedicated to transforming the treatment of substance use disorders (SUDs), particularly opioid use disorder (OUD). Its key products include SUBLOCADE, SUBOXONE Film, and OPVEE, addressing both OUD and opioid overdose. With a significant market opportunity driven by rising addiction rates, Indivior targets healthcare providers and patients in over 30 countries. The company emphasizes compliance and innovation, recently launching OPVEE and expanding SUBLOCADE's administration options.

Company Website

This description was generated via AI from an annual report. Updated about 1 year ago.

About 10-K Filings

A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.

Key points about the 10-K:

  • Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
  • Content: It includes:
    • Detailed financial statements audited by an independent accounting firm
    • Management's Discussion and Analysis (MD&A) of financial condition and results
    • Description of the company's business, properties, and legal proceedings
    • Risk factors and market risks
    • Executive compensation and corporate governance information
  • Importance: Considered the most comprehensive and important document a public company files with the SEC.
  • Length: Often exceeds 100 pages due to its extensive and detailed nature.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.

View the complete official filing on the SEC website.

Read on SEC.gov